Literature DB >> 2894481

Tumor regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201-995.

B Wiedenmann1, U Räth, R Rädsch, F Becker, B Kommerell.   

Abstract

A 53-year-old man with metastatic ileal carcinoid ultimately failed to respond to conventional measures of surgery and was finally treated with a new long acting somatostatin analogue, SMS 201-995 for 7 months. SMS 201-995 not only gave symptomatic relief but also induced a reduction in metastatic tumor mass.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2894481     DOI： 10.1007/bf01713015

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


  14 in total

1.  Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.

Authors:  L K Kvols; C G Moertel; M J O'Connell; A J Schutt; J Rubin; R G Hahn
Journal:  N Engl J Med       Date:  1986-09-11       Impact factor: 91.245

2.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

Authors:  W Bauer; U Briner; W Doepfner; R Haller; R Huguenin; P Marbach; T J Petcher
Journal:  Life Sci       Date:  1982-09-13       Impact factor: 5.037

3.  Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera.

Authors:  P N Maton; T M O'Dorisio; B A Howe; K E McArthur; J M Howard; J A Cherner; T B Malarkey; M J Collen; J D Gardner; R T Jensen
Journal:  N Engl J Med       Date:  1985-01-03       Impact factor: 91.245

Review 4.  Somatostatin localization in tissues.

Authors:  J M Polak; S R Bloom
Journal:  Scand J Gastroenterol Suppl       Date:  1986

5.  Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses.

Authors:  S M Wood; M E Kraenzlin; T E Adrian; S R Bloom
Journal:  Gut       Date:  1985-05       Impact factor: 23.059

6.  The carcinoid flush. Provocation by pentagastrin and inhibition by somatostatin.

Authors:  J C Frölich; Z T Bloomgarden; J A Oates; J E McGuigan; D Rabinowitz
Journal:  N Engl J Med       Date:  1978-11-09       Impact factor: 91.245

7.  Effect of somatostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera.

Authors:  A Ruskoné; E René; J A Chayvialle; N Bonin; F Pignal; M Kremer; S Bonfils; J C Rambaud
Journal:  Dig Dis Sci       Date:  1982-05       Impact factor: 3.199

8.  Somatostatin, gastrointestinal peptides, and the carcinoid syndrome.

Authors:  R G Long; J R Peters; S R Bloom; M R Brown; W Vale; J E Rivier; D G Grahame-Smith
Journal:  Gut       Date:  1981-07       Impact factor: 23.059

9.  Colorimetric assay of urinary 5-hydroxy-3-indoleacetic acid.

Authors:  Z K Shihabi; E L Wilson
Journal:  Clin Biochem       Date:  1982-04       Impact factor: 3.281

10.  Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man.

Authors:  M Sheppard; B Shapiro; B Pimstone; S Kronheim; M Berelowitz; M Gregory
Journal:  J Clin Endocrinol Metab       Date:  1979-01       Impact factor: 5.958
View more
  7 in total

1.  [2 year interferon therapy of metastatic carcinoid tumor].

Authors:  W von Scheidt; M Böhm; I Huber; R Habersetzer; K Jacob; A Markl; G Autenrieth
Journal:  Klin Wochenschr       Date:  1990-02-15

2.  Occult retroperitoneal carcinoid tumor with flushing and solitary lung metastasis.

Authors:  J A Jackson; H D Shipman
Journal:  West J Med       Date:  1989-10

Review 3.  Somatostatin and analogues in the treatment of cancer. A review.

Authors:  B M Evers; D Parekh; C M Townsend; J C Thompson
Journal:  Ann Surg       Date:  1991-03       Impact factor: 12.969

4.  Palliative therapy of an ectopic Cushing's syndrome due to a metastatic carcinoid tumor.

Authors:  E Kornely; R Schlaghecke; F A Horster
Journal:  Klin Wochenschr       Date:  1991-02-26

5.  Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

Authors:  R Arnold; M E Trautmann; W Creutzfeldt; R Benning; M Benning; C Neuhaus; R Jürgensen; K Stein; H Schäfer; C Bruns; H J Dennler
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

6.  Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors.

Authors:  R Arnold; C Neuhaus; R Benning; W B Schwerk; M E Trautmann; K Joseph; C Bruns
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

Review 7.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.